An updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the company announced Tuesday. While the biotech plans to use the data to apply for regulatory approval, cancer specialists say they’ll need to see more details before concluding the new test is a real and meaningful improvement over the current one.
The results come from a 20,000-person study of a new version of the company’s Cologuard test, which detects molecular markers of cancer in patients’ feces. Participants in the trial, dubbed Blue-C, received either the updated Cologuard test or a so-called fecal immunochemical test, or FIT, which detects blood in stool. The new Cologuard test correctly detected cancer 94% of the time, and it correctly returned a negative result 91% of the time, test characteristics known as sensitivity and specificity, respectively.
A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. Put differently, Cologuard returned false positive results 13% of the time in the earlier study among people who don’t have cancerous cells or cells that show early signs of transforming into cancer, compared to a 9% false positive rate with this next version of the test.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect